Evidence map›Paper›PMID 21843349›Full record

ArticleBMC musculoskeletal disorders2011

The proteasome inhibitor MG132 reduces immobilization-induced skeletal muscle atrophy in mice.

Annabelle Z Caron, Sonia Haroun, Elisabeth Leblanc, Frédéric Trensz, Chantal Guindi, Aziz Amrani, Guillaume Grenier

Open access · goldAbstract read
In one paragraph

Article in BMC musculoskeletal disorders, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 50 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
50citing papers in PubMed, 1 pooled it
2.5field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

50 citing papers in PubMed, 1 synthesis or guideline pooled it, 75 citations in OpenAlex.

  1. Pooled it
  2. Leonurine-StandardizedJournal of microbiology and biotechnology · 2026
    Article
  3. Article
  4. Article
  5. Article
  6. BCL6 coordinates muscle mass homeostasis with nutritional states.Proceedings of the National Academy of Sciences of the United States of America · 2025
    Article
  7. Article
  8. Article
  9. Targeting MuRF1 to Combat Skeletal Muscle Wasting in Cardiac Cachexia: Mechanisms and Therapeutic Prospects.Medical science monitor : international medical journal of experimental and clinical research · 2024
    Review
  10. Review
  11. Article
  12. Review
  13. Review
  14. HFrontiers in physiology · 2022
    Article
  15. Article
  16. Article
  17. Article
  18. Review
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Annabelle Z CaronCentre de Recherche Clinique Étienne-Lebel, 3001-12th Avenue North, Sherbrooke, QC J1H5N4, Canada.
Sonia Haroun
Elisabeth Leblanc
Frédéric Trensz
Chantal Guindi
Aziz Amrani
Guillaume Grenier
Q & T Research · CAUniversité de Sherbrooke · CA

Funding

Canadian Institutes of Health Research
6 · The paper itself

Abstract

backgroundSkeletal muscle atrophy is a serious concern for the rehabilitation of patients afflicted by prolonged limb restriction. This debilitating condition is associated with a marked activation of NFκB activity. The ubiquitin-proteasome pathway degrades the NFκB inhibitor IκBα, enabling NFκB to translocate to the nucleus and bind to the target genes that promote muscle atrophy. Although several studies showed that proteasome inhibitors are efficient to reduce atrophy, no studies have demonstrated the ability of these inhibitors to preserve muscle function under catabolic condition.

methodsWe recently developed a new hindlimb immobilization procedure that induces significant skeletal muscle atrophy and used it to show that an inflammatory process characterized by the up-regulation of TNFα, a known activator of the canonical NFκB pathway, is associated with the atrophy. Here, we used this model to investigate the effect of in vivo proteasome inhibition on the muscle integrity by histological approach. TNFα, IL-1, IL-6, MuRF-1 and Atrogin/MAFbx mRNA level were determined by qPCR. Also, a functional measurement of locomotors activity was performed to determine if the treatment can shorten the rehabilitation period following immobilization.

resultsIn the present study, we showed that the proteasome inhibitor MG132 significantly inhibited IκBα degradation thus preventing NFκB activation in vitro. MG132 preserved muscle and myofiber cross-sectional area by downregulating the muscle-specific ubiquitin ligases atrogin-1/MAFbx and MuRF-1 mRNA in vivo. This effect resulted in a diminished rehabilitation period.

conclusionThese finding demonstrate that proteasome inhibitors show potential for the development of pharmacological therapies to prevent muscle atrophy and thus favor muscle rehabilitation.

Indexed as

Proteasome InhibitorsAnimalsCell LineCysteine Proteinase InhibitorsDisease Models, AnimalHindlimb SuspensionLeupeptinsMaleMiceMice, Inbred StrainsMuscle, SkeletalMuscular AtrophyProteasome Endopeptidase Complexbenzyloxycarbonylleucyl-leucyl-leucine aldehydeCysteine Proteinase InhibitorsLeupeptinsProteasome Endopeptidase ComplexProteasome Inhibitors

Identifiers

PMID21843349
PMCPMC3173404
OpenAlexW2094585730

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.